SureTrader
Home > Boards > US Listed > Biotechs > Compugen (CGEN)

Yep its posted:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DAD2 Member Profile
 
Followed By 64
Posts 5,263
Boards Moderated 0
Alias Born 03/11/09
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2018 9:09:30 AM
Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET PR Newswire (US) - 2/8/2018 7:00:00 AM
Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoim... PR Newswire (US) - 2/6/2018 7:06:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/6/2018 7:02:19 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 1/31/2018 4:58:30 PM
Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the... PR Newswire (US) - 1/18/2018 7:00:00 AM
Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences PR Newswire (US) - 1/2/2018 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 12/18/2017 6:05:56 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/7/2017 7:32:14 AM
Compugen Reports Third Quarter 2017 Results PR Newswire (US) - 11/7/2017 7:10:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/6/2017 8:01:08 AM
Compugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal Antibody PR Newswire (US) - 11/6/2017 7:00:00 AM
Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets PR Newswire (US) - 11/2/2017 7:00:00 AM
Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month PR Newswire (US) - 10/26/2017 7:00:00 AM
Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET PR Newswire (US) - 10/25/2017 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/19/2017 9:41:56 AM
A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy PR Newswire (US) - 10/9/2017 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/6/2017 7:10:35 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 8/14/2017 3:33:21 PM
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month PR Newswire (US) - 8/7/2017 7:00:00 AM
Compugen Welcomes Paul Sekhri as its New Chairman of the Board PR Newswire (US) - 8/2/2017 7:22:00 AM
Compugen Reports Second Quarter 2017 Results PR Newswire (US) - 8/2/2017 7:20:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/2/2017 7:18:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/26/2017 7:31:02 AM
Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology PR Newswire (US) - 7/26/2017 7:09:00 AM
DAD2   Tuesday, 02/07/12 07:23:17 AM
Re: Penny Roger$ post# 111
Post # of 160 
Yep its posted:

Zero revenues in the 4th quarter and the net loss for the 4th quarter was $4.4 million.

Might pull back slightly imo.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist